Twirla

I am eagerly awaiting the FDA's decision on Twirla and look forward to sharing in equity value creation with fellow shareholders.

I have not been confident in my AGRX position ever since Agile announced the FDA had accepted Twirla's NDA resubmission but did not schedule an AdCom.